Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Authors:
- Theresa A. ZesiewiczTZTheresa A. Zesiewicz
- Kelly L. SullivanKSKelly L. Sullivan
- John L. MaldonadoJMJohn L. Maldonado
- William O. TatumWTWilliam O. Tatum
- 13 June 2005
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 20 (9) , 1205-1209
Abstract
We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder SocietyKeywords
This publication has 22 references indexed in Scilit:
- Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymomaJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Parkinson's disease home diary: Further validation and implications for clinical trialsMovement Disorders, 2004
- Substantial improvement in a Meige's syndrome patient with levetiracetam treatmentMovement Disorders, 2004
- Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmosetMovement Disorders, 2003
- A community‐based study of sleep disorders in patients with Parkinson's diseaseMovement Disorders, 1998
- Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's diseaseNeurology, 1997
- Ropinirole for the treatment of early Parkinson's diseaseNeurology, 1997
- The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine has potent antidystonic efficacy in a genetic animal model of dystoniaEuropean Journal of Pharmacology, 1993
- Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's diseaseNature, 1988
- Analysis of L-dopa induced dyskinesias in 51 patients with ParkinsonismJournal of Neurology, Neurosurgery & Psychiatry, 1971